An artificial pancreas is a wearable system that automatically monitors blood sugar and delivers insulin with minimal input from the person wearing it. It doesn’t replace the organ itself. Instead, it combines a continuous glucose monitor (CGM), an insulin pump, and a software algorithm that connects the two, mimicking the way a healthy pancreas would respond to rising and falling blood sugar throughout the day.
These systems are already commercially available and used by thousands of people with type 1 diabetes. They represent a significant shift from traditional insulin management, where every dose requires a manual decision.
The Three Core Components
Every artificial pancreas system has three parts working together. The first is a continuous glucose monitor, a small sensor inserted just under the skin that reads blood sugar levels every few minutes and wirelessly transmits the data. The second is an insulin pump, a small device that delivers precise amounts of insulin through a thin tube (called an infusion set) or a patch stuck to the body. The third, and most important, is the control algorithm: software that takes the glucose readings, predicts where blood sugar is heading, and tells the pump how much insulin to deliver.
The algorithm is what makes the system “artificial.” It automates the constant decision-making that people with type 1 diabetes otherwise have to do themselves, adjusting insulin delivery in response to meals, exercise, sleep, and stress. The sensor and pump are the hardware. The algorithm is the brain.
How the Algorithm Decides
The software running these systems generally uses one of two main approaches. The most common is called model predictive control, which builds a mathematical model of how your body responds to insulin and uses it to forecast where your blood sugar will be in the near future. It then adjusts delivery to steer toward a target, accounting for how much insulin is already active in your system.
The other approach reacts to three things at once: how far your current blood sugar is from the target, how long it’s been elevated or low (the accumulated gap over time), and how fast it’s changing right now. A less common third method attempts to mimic the reasoning of an experienced diabetes clinician, applying a set of if-then rules rather than pure math. In practice, most commercial systems today use the predictive model approach.
Hybrid vs. Fully Closed Loop
Most systems available today are “hybrid” closed-loop systems. The word hybrid means you still need to do some of the work. Specifically, you tell the system when you’re about to eat and enter your carbohydrate count so it can deliver a mealtime insulin dose. Between meals and overnight, the system runs on its own, adjusting background insulin delivery automatically. But it can’t fully handle the large, fast blood sugar spikes that come from food without some advance notice.
Fully closed-loop systems aim to eliminate meal announcements entirely. In clinical trials, researchers have tested systems that pair a faster-acting insulin with a second drug to slow digestion, allowing the algorithm to manage meals without any input from the user. These fully automated designs are still largely in the research phase for everyday use, though dual-hormone systems (described below) have demonstrated the concept works.
Dual-Hormone Systems
A standard artificial pancreas delivers only insulin, which lowers blood sugar. But a healthy pancreas also releases glucagon, a hormone that raises blood sugar when it drops too low. Dual-hormone (or “bihormonal”) systems carry both insulin and glucagon, giving the algorithm a tool for correcting in both directions.
The clinical results for these systems are striking. In a trial involving patients who had their entire pancreas surgically removed (meaning they produce zero insulin or glucagon), a bihormonal system kept blood sugar in the target range of 70 to 180 mg/dL about 78% of the time, compared to 57% with standard insulin pump or pen therapy. Time spent with dangerously low blood sugar dropped to essentially zero. Overnight, the improvement was even more dramatic: patients spent nearly 95% of nighttime hours in range versus about 48% with conventional care. No serious adverse events were reported, and most patients said the system freed them from years of restricting certain foods and activities.
Systems Available Today
Several FDA-cleared automated insulin delivery systems are currently on the U.S. market. The major options include the Tandem t:slim X2 and Tandem Mobi with Control-IQ technology, the Omnipod 5 (a tubeless patch pump), the Medtronic MiniMed 780G, and the Beta Bionics iLet. A newer entry, the twiist system powered by Tidepool, is also available, along with a DIY option called Tidepool Loop for people who want to build their own setup with compatible hardware.
These systems differ in meaningful ways. The iLet, for example, takes a notably simpler approach to setup. It only requires your body weight to initialize. There are no basal rates, insulin-to-carb ratios, correction factors, or profiles to program. When you eat, you don’t count carbohydrates. Instead, you simply tell the system whether the meal is breakfast, lunch, or dinner and whether it has your usual amount of carbs, more, or less. The algorithm figures out dosing on its own, recalibrating every five minutes. Most other systems, like Control-IQ, still require you to set up detailed personal profiles including basal rates, carb ratios, and correction factors.
What You Manage Day to Day
Wearing an artificial pancreas isn’t completely hands-free. You need to replace the CGM sensor periodically, typically every 7 to 14 days depending on the brand. The insulin infusion set, the small cannula that sits under your skin and delivers insulin, is approved for about 3 days of use, though some people stretch them to 4 to 6 days. Studies show glucose control tends to worsen after day 3 of continuous use, so timely changes matter. The mismatch between sensor life and infusion set life means you’re swapping out different components on different schedules.
You also need to keep the pump filled with insulin, charge or replace batteries, and in hybrid systems, announce meals. Sensors occasionally lose signal or give inaccurate readings, requiring a fingerstick to confirm. The system reduces the mental burden of diabetes significantly, but it doesn’t eliminate it.
How Much It Improves Blood Sugar Control
The clearest way to measure an artificial pancreas system’s benefit is “time in range,” the percentage of the day your blood sugar stays between 70 and 180 mg/dL. In a trial of very young children with type 1 diabetes (one of the hardest populations to manage), hybrid closed-loop use increased time in range by about 8.5 percentage points compared to a standard sensor-augmented pump, bringing the average to roughly 70%. That improvement held steady over 18 months of use. HbA1c, the standard measure of long-term blood sugar control, dropped by 0.4 percentage points.
Those numbers might sound modest in isolation, but an 8-point increase in time in range translates to roughly two more hours per day with blood sugar in a healthy zone. Over months and years, that meaningfully reduces the risk of diabetes complications. The benefits are especially notable overnight, when blood sugar swings are hardest to catch manually.
Cost and Insurance Coverage
The total cost of an artificial pancreas system includes the pump itself, CGM sensors, infusion sets, and insulin. Under Medicare, insulin pumps are covered as durable medical equipment under Part B, and insulin used with those pumps is also covered under Part B with a cap of $35 per month per insulin product and no deductible. Patch-style pumps that are replaced every few days may be covered under Part D drug plans instead. Most private insurers cover automated insulin delivery systems, though prior authorization and documentation of need are common requirements.
Out-of-pocket costs vary widely depending on your plan. The pump hardware can cost several thousand dollars before insurance, and ongoing supplies (sensors, infusion sets, insulin) add recurring monthly expenses. Many manufacturers offer financial assistance programs, and the trend in recent years has been toward broader coverage as clinical evidence supporting these systems has grown.